pharmaphorum

AUGUST 2, 2022

As the technology has developed, the interest from larger pharma companies has continued to grow, resulting in a number of acquisitions and partnerships taking place to gain access to the technology. Looking to the future. billion in revenue last year.

Marketing 98

Marketing Prospecting Sales Pharma 98

PM360

APRIL 7, 2023

No one has ever described the pharma market access landscape as simple or easy to understand, and the passage of the Inflation Reduction Act (IRA) is not likely to change that. Pharma manufacturers of brands that are selected for negotiation will absolutely want to ‘pull through’ their coveted, newfound formulary position with HCPs.

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

Pharmaceutical Technology

JANUARY 19, 2023

Antigens such as CD123 and CD33, despite being markers of myeloid cells, are shared with their healthy counterparts, and myeloablation following their depletion often leads to detrimental clinical outcomes. GlobalData’s Pharma Intelligence Center shows 19 autologous CAR-T cell products in Phase I, and nine products in Phase II, globally.

Marketing 52

Marketing FDA Sales Management 52

pharmaphorum

OCTOBER 18, 2022

Eli Lilly has agreed to buy hearing loss gene therapy developer Akouos in a deal that could value the company at around $610 million – if its lead candidate progresses as hoped in the clinic. per month if conditions are not met, until the end of 2028 when they will all expire. The buyout – for $12.50

Medicine 52

Medicine FDA Patients Pharma 52

European Pharmaceutical Review

NOVEMBER 30, 2023

For example, the GMP report stated that the contract development and manufacturing organisation (CDMO) eXmoor pharma, will be launching a cell and gene therapy process development and clinical manufacturing facility in Bristol. Licensing of the manufacturing suites is expected in early 2024.

Manufacturing 97

Manufacturing Recruitment Medicine Biopharma 97

Pharmaceutical Representative Training

JANUARY 29, 2025

Market Competition: Another similarity that biosimilars have to generics is that there can be multiple biosimilars for the same reference product, leading to competition for shares in the market. link] The post Biosimilars: The Future of Affordable Biologic Therapies appeared first on Pharma Sales Training. 4] References: 1.

Marketing 52

Marketing Healthcare Healthcare Physicians 52

Pharmaceutical Technology

FEBRUARY 13, 2023

This makes early R&D less risky, as many lead compounds are discontinued due to inadequate pharmacokinetic profiles and require excessively high dosages to be pharmaceutically active. Non-small cell lung cancer leads as the indication with the highest number of PROTACs in the pipeline, currently sitting at 11 preclinical candidates.

Competition 59

Competition Safety Patients Pharmaceutical 59

Clarivate

MAY 13, 2024

In March 2024, New York received approval for a five-year Medicaid expansion through April 1, 2028, extending eligibility to include individuals with incomes up to 250% of the federal poverty level (eligibility was previously capped at 200%). Pillo, Senior Healthcare Research and Data Analyst. The post The U.S.

Insurance 52

Insurance Marketing Healthcare Healthcare 52

Pharmaceutical Technology

DECEMBER 22, 2022

The new joint procedure will launch in Q1 2025 for oncology medicines and other advanced therapy medicinal products and extend to orphan drugs in 2028. Beyond that, they thought the collaboration could lead to mutual learning that could drive positive changes across the continent. Will the joint procedure drive positive change?

Medicine 52

Medicine Pharma Marketing Distribution 52

Clarivate

OCTOBER 25, 2023

The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. Part D cannot cover drugs covered under Part A or Part B , forcing them to be addressed separately.

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Pharmaceutical Technology

MAY 30, 2023

According to GlobalData’s Looking Ahead to 2023 – the Future of Pharma report, five drugs set for approval in 2023 are projected to attain blockbuster status or near-blockbuster status by 2028 with US company dominance. These drugs are set to make a combined $4.34bn in sales in 2028.

Sales 105

Sales Marketing Prescription Pharma 105

pharmaphorum

OCTOBER 10, 2022

As part of efforts to increase uptake of screening programmes, purpose-driven partnerships between the NHS and the pharma industry have emerged as an innovative solution to raise patient awareness. The goal set out by the NHSE Long Term Plan is ambitions: to have three quarters of cancers diagnosed at an early stage by 2028.

Patients 98

Patients Pharma Media Training 98

World of DTC Marketing

MARCH 17, 2021

The rapid rollout of Covid-19 vaccines has made household names of Pfizer and AstraZeneca, and the whole industry is winning praise for co-operation” However, the bump in reputation will be short-lived because companies need to earn the public’s trust every day, and pharma is already damaging their perception with people.

Pharma 186

Pharma Competition Prescription Sales 186

European Pharmaceutical Review

AUGUST 15, 2022

According to GAVI – the Vaccine Alliance, the drug maker had already agreed to cut its deliveries of rotavirus vaccine by 10 million a year between 2022 and 2028. The pharma giant is not the only company facing challenges in the area, GAVI has also been warned of delays with Bharat Biotech’s rotavirus vaccine, Rotavac.

Manufacturing 98

Manufacturing Pharma Leads Pharmaceutical 98

European Pharmaceutical Review

OCTOBER 12, 2023

AstraZeneca’s facilities in Macclesfield, the UK’s largest pharma manufacturing site, as well as Cambridge, Luton and Speke will all be supplied by energy from the new facility, which is currently being built. Astellas – sustainable innovation September also saw Astellas Pharma Inc. Kerry, Ireland.

Pharmaceutical manufacturing 104

Pharmaceutical manufacturing Manufacturing Pharmaceutical Pharma 104

Pharmaceutical Technology

MAY 16, 2023

trillion in Q1 2023, according to GlobalData’s pharma intelligence centre companies database. This growth is expected to continue, with a 62% growth in annual consensus sales forecast from 2023 to 2028, fuelled by the company’s semaglutide portfolio, according to GlobalData’s report, ‘Looking ahead to 2023 – the future of pharma’.

Marketing 52

Marketing Sales Pharma Leads 52

World of DTC Marketing

SEPTEMBER 9, 2021

SUMMARY: Allowing Medicare to negotiate drug prices is popular with voters because the media has been focused on the high price of some drugs, but this measure won’t lead to lower healthcare costs. The drug industry is trying to convince voters that government negotiations with drug companies will lead to less innovation.

Healthcare 222

Healthcare Healthcare Government Insurance 222

Pharmaceutical Technology

APRIL 27, 2023

When combined with rapid advancement in delivery technologies, mRNA has the potential to lead to breakthroughs in the development of tailored treatment approaches in a wide range of indications from cancer to rare genetic disorders while enabling rapid responses to emerging threats. billion by 2028.

Manufacturing 52

Manufacturing Marketing Medicine Transportation 52